Cipla Annualised Returns
1 Year
▼-15.13%
3 Years
▲12.45%
5 Years
▲7.42%
10 Years
▲9.14%
Cipla Share Price Today
As of 25 Apr 2026, Cipla share price is ₹1295. The stock opened at ₹1295 and had closed at ₹1305.9 the previous day. During today’s trading session, Cipla share price moved between ₹1,254.10 and ₹1,303.90, with an average price for the day of ₹1279.00. Over the last 52 weeks, the stock has recorded a low of ₹1,165.70 and a high of ₹1,673.00. In terms of performance, Cipla share price has declined by 18.3% over the past six months and has declined by 15.13% over the last year.
Cipla Stock Performance
|
|
|
Cipla Share Price Chart
Cipla Company background
Cipla Overview
Cipla Limited was founded in 1935 by Khwaja Abdul Hamied and incorporated under its present name in 1984. Headquartered in Mumbai, Maharashtra, the company is listed on both NSE (CIPLA) and BSE (500087). It is a global pharmaceutical major focused on developing, manufacturing, and marketing generic and branded medicines across areas such as respiratory, cardiovascular, anti-retroviral, oncology, and consumer healthcare, both in India and internationally.
Cipla Business Segments and Revenue Model
Cipla operates through key verticals: Generic Pharmaceuticals, Branded Pharmaceuticals, Active Pharmaceuticals Ingredients (API), Specialty Therapies (including oncology and respiratory), and Consumer Healthcare. It generates revenue through the sale of pharmaceutical products to hospitals, clinics, and retailers, as well as through exports. Net interest income, though minimal, comes from its treasury investments. Its diverse global presence in markets like the US, Africa, and Europe ensures balanced revenue, with R&D-led specialty products enhancing margins alongside scale-driven generics.
Cipla Key Milestones
- 1935: Founded in Mumbai as Chemical, Industrial & Pharmaceutical Laboratories
- 1984: Renamed Cipla Limited
- 1995: Launched Deferiprone, the world’s first oral iron chelator
- 2006: Acquired remdesivir licence, launched Cipremi in India
- 2013: Acquired Cipla-Medpro (South Africa)
- 2015: Acquired U.S. generics firms InvaGen and Exelan for $555 million
- 2019: Ventured into digital therapeutics via partnerships in India and South Africa
- 2023: Acquired cosmetics distribution business of Ivia Beaute for ₹130 crore
- May 2025: Announced a combined ₹16/share dividend to mark its 90th anniversary
Cipla ESG and Sustainability
- CSR focus includes access to healthcare, education, women’s empowerment, and community health initiatives
- ESG mission emphasises strengthening healthcare access globally and reducing environmental impact through sustainable manufacturing and energy efficiency
- Long-term goal to align with global sustainability benchmarks and foster inclusive growth
Cipla Awards and Recognitions
- Thomson Reuters India Innovation Award (2012)
- Featured in Forbes “200 Best Under a Billion” list (2007)
- Chemexcil Award for excellence in exports (1980)
- Consistently recognised for innovation, quality, and corporate governance
Cipla Financial Highlights
Cipla Fundamental
Market Cap (in crs)
1,04,607.85
Face Value
2
Turnover (in lacs)
57,333.63
Key Metrics
Cipla Key Financials
View more7074.48 Cr | 7589.44 Cr | 6957.47 Cr | 6729.69 Cr | 7072.97 Cr |
28409.49 Cr | 26520.66 Cr | 23228.57 Cr | 22044.25 Cr | 19425.58 Cr | 17476.19 Cr |
674.56 Cr | 1353.07 Cr | 1292.05 Cr | 1225.02 Cr | 1583.72 Cr |
5291.05 Cr | 4155.31 Cr | 2835.49 Cr | 2559.47 Cr | 2401.3 Cr | 1546.98 Cr |
Cipla Result Highlights
-
Cipla reported a 7.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 0.2%.
-
Its expenses for the quarter were up by 1.8% QoQ and 13.6% YoY.
-
The net profit decreased 50.2% QoQ and decreased 57.2% YoY.
-
The earnings per share (EPS) of Cipla stood at 8.36 during Q3 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Cipla Technical Analysis
Delivery Volume %
Day
46.50%
Week
51.80%
Month
58.70%
Delivery & Volume
Day Rs | 2117319 Rs | 4552968 Rs |
Week Rs | 1562183 Rs | 3015519 Rs |
Month Rs | 1451379 Rs | 2471563 Rs |
Resistance & Support
Cipla Peer comparison
Compare1,413.80 -21.60 (-1.50%)▼ | |
927.40 -18.95 (-2.00%)▼ | |
1,317.10 -13.90 (-1.04%)▼ | |
2,296.10 -45.30 (-1.93%)▼ | |
4,117.20 -30.00 (-0.72%)▼ | |
2,267.40 -25.50 (-1.11%)▼ |
Cipla Latest News
Cipla Share Price FAQs
Cipla share price is ₹1295 in NSE and ₹1294.75 in BSE as on 24/4/2026.
Cipla share price in the past 1-year return was -16.54. The Cipla share hit a 1-year low of Rs. 1165.7 and a 1-year high of Rs. 1673.
The market cap of Cipla is Rs. 104607.85 Cr. as of 24/4/2026.
The PE ratios of Cipla is 22.66 as of 24/4/2026.
The PB ratios of Cipla is 3.14 as of 24/4/2026
The Mutual Fund Shareholding in Cipla was 18.66% at the end of 24/4/2026.
You can easily buy Cipla shares in Kotak Neo by opening a demat account and getting the KYC documents verified online.
The 52-week high and low of Cipla share price is ₹1673 and ₹1165.7 as of 24/4/2026.
Please be aware that Cipla stock prices are subject to continuous fluctuations due to various factors.
Popular Stocks | |||||||||
303.44 -3.77 (-1.23%)▼ | |||||||||
210.07 -0.84 (-0.40%)▼ | |||||||||
256.79 -3.13 (-1.20%)▼ | |||||||||
444.45 -5.50 (-1.22%)▼ | |||||||||
435.00 +4.70 (+1.09%)▲ | |||||||||
Top Gainers | |||||||||
456.00 +5.35 (+1.19%)▲ | |||||||||
4,297.30 +45.90 (+1.08%)▲ | |||||||||
1,421.30 +10.80 (+0.77%)▲ | |||||||||
1,048.35 +7.00 (+0.67%)▲ | |||||||||
1,101.10 +6.85 (+0.63%)▲ | |||||||||
Top Losers | |||||||||
1,154.60 -86.00 (-6.93%)▼ | |||||||||
1,203.20 -74.40 (-5.82%)▼ | |||||||||
2,396.90 -124.90 (-4.95%)▼ | |||||||||
1,358.50 -63.00 (-4.43%)▼ | |||||||||
1,620.40 -59.70 (-3.55%)▼ | |||||||||